Group items tagged

Teva UK has begun replacing its existing packaging with a new design which is "clearer and easier to read". The new look is "unique, recognisable and distinctive." It "enhances safety and provides a recognisable and distinguishable pack range." One of the UK's leading generics manufacturers, Teva UK supplies more than 500 generic pharmaceutical products to retail and hospital pharmacies. The company says each product within the portfolio is distinguishable by colour, ensuring no two different packs have the same drug and strength colours and with additional product information on the side of the pack and a simplified back, it makes it even easier to identify the correct product when dispensing and supports patients when taking their medication. "Our medicines impact the lives of millions of people every day and our packaging is often the first touchpoint for our patients and our customers", said Kim Innes, general manager of Teva UK and Ireland.

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.